

Camilla Nero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4522448/publications.pdf>

Version: 2024-02-01

35
papers

624
citations

516215

16
h-index

642321

23
g-index

35
all docs

35
docs citations

35
times ranked

845
citing authors

#	ARTICLE	IF	CITATIONS
1	Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer. <i>Fertility and Sterility</i> , 2022, 117, 160-168.	0.5	6
2	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. <i>Gynecologic Oncology</i> , 2022, 165, 585-593.	0.6	10
3	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
4	Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital. <i>Journal of Personalized Medicine</i> , 2022, 12, 3.	1.1	4
5	Further refining 2020 ESCO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis. <i>Cancer</i> , 2022, 128, 2898-2907.	2.0	6
6	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	1.9	9
7	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.	1.7	24
8	Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 116.	3.5	23
9	Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. <i>Cancers</i> , 2021, 13, 2089.	1.7	20
10	Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment. <i>Frontiers in Oncology</i> , 2021, 11, 612450.	1.3	9
11	PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 5200.	1.7	6
12	Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103542.	2.0	3
13	Newly diagnosed ovarian cancer: Which first-line treatment?. <i>Cancer Treatment Reviews</i> , 2020, 91, 102111.	3.4	23
14	Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study). <i>Scientific Reports</i> , 2020, 10, 16511.	1.6	15
15	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	1.0	15
16	Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 712-713.	1.2	5
17	Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.	0.5	3
18	Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 324.e1-324.e10.	0.7	59

#	ARTICLE	IF	CITATIONS
19	Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY). <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1437-1439.	1.2	19
20	PTEN and Gynecological Cancers. <i>Cancers</i> , 2019, 11, 1458.	1.7	35
21	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1064-1071.	1.2	2
22	Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 774-775.	0.3	5
23	Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. <i>Gynecologic Oncology</i> , 2018, 149, 263-269.	0.6	35
24	Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 644-650.	0.3	49
25	Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. <i>Annals of Surgical Oncology</i> , 2018, 25, 247-254.	0.7	10
26	One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. <i>PLoS ONE</i> , 2018, 13, e0195877.	1.1	29
27	Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 133-139.	0.3	23
28	A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment. <i>Gynecologic Oncology</i> , 2016, 142, 19-24.	0.6	41
29	Laparoscopic Management of a Small Bowel Recurrence of Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 160.	0.3	2
30	Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 425-428.	0.3	10
31	Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 877-883.	0.3	25
32	Minilaparoscopic Aortic Lymphadenectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 546-547.	0.3	3
33	Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1808-1815.	1.3	44
34	Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations. <i>Annals of Surgical Oncology</i> , 2014, 21, 2369-2375.	0.7	29
35	Immunotherapy in gynecological cancers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1